These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25538270)

  • 21. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
    Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
    Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
    Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
    Madhi SA; Izu A; Violari A; Cotton MF; Panchia R; Dobbels E; Sewraj P; van Niekerk N; Jean-Philippe P; Adrian PV;
    Vaccine; 2013 Jan; 31(5):777-83. PubMed ID: 23228814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.
    Abzug MJ; Song LY; Levin MJ; Nachman SA; Borkowsky W; Pelton SI;
    Vaccine; 2013 Oct; 31(42):4782-90. PubMed ID: 23954381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired serotype-specific immune function following pneumococcal vaccination in infants with prior carriage.
    Licciardi PV; Russell FM; Balloch A; Burton RL; Nahm MH; Gilbert G; Tang ML; Mulholland EK
    Vaccine; 2014 Apr; 32(20):2321-7. PubMed ID: 24613524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
    Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
    Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV.
    Talesnik E; Vial PA; Labarca J; Méndez C; Soza X
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):471-7. PubMed ID: 9859960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.
    Romaru J; Bahuaud M; Lejeune G; Hentzien M; Berger JL; Robbins A; Lebrun D; N'Guyen Y; Bani-Sadr F; Batteux F; Servettaz A
    Front Immunol; 2021; 12():791147. PubMed ID: 34987514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.
    Karlsson J; Roalfe L; Hogevik H; Zancolli M; Andréasson B; Goldblatt D; Wennerås C
    Clin Vaccine Immunol; 2016 Apr; 23(4):379-85. PubMed ID: 26912783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
    Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
    Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
    Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
    AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dependence of correlations between antibody titres and opsonophagocytosis on pneumococcal serotype and patient morbidity in pre- and post-pneumococcal vaccination states.
    Tarragó D; Aguilar L; Jansen WT; Giménez MJ; Avellón A; Granizo JJ; Casal J
    Clin Microbiol Infect; 2007 Apr; 13(4):369-76. PubMed ID: 17359320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
    Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
    Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children.
    Cho HK; Park IH; Burton RL; Kim KH
    J Korean Med Sci; 2016 Jun; 31(6):950-6. PubMed ID: 27247505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.